Measurable residual disease testing for personalized treatment of acute myeloid leukemia.

J.F. San Miguel, A. Martı́nez, A. Macedo, M.B. Vidriales, C. López-Berges, M. González, D. Caballero, M.A. Garcı́a-Marcos, F. Ramos, J. Fernández-Calvo, M.J. Calmuntia, J. Diaz-Mediavilla, A. Orfao, Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients Blood. ,vol. 90, pp. 2465- 2470 ,(1997) , 10.1182/BLOOD.V90.6.2465

Cancer Genome Atlas Research Network, None, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia The New England Journal of Medicine. ,vol. 368, pp. 2059- 2074 ,(2013) , 10.1056/NEJMOA1301689

Jean-Claude Chomel, Françoise Brizard, Anne Veinstein, Jérôme Rivet, Alain Sadoun, Alain Kitzis, François Guilhot, André Brizard, Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-α therapy or allogeneic bone marrow transplantation Blood. ,vol. 95, pp. 404- 408 ,(2000) , 10.1182/BLOOD.V95.2.404

ME Huang, YC Ye, SR Chen, JR Chai, JX Lu, L Zhoa, LJ Gu, ZY Wang, Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia Blood. ,vol. 72, pp. 567- 572 ,(1988) , 10.1182/BLOOD.V72.2.567.567

María-Belén Vidriales, Estefanía Pérez-López, Carlota Pegenaute, Marta Castellanos, José-Juan Pérez, Mauricio Chandía, Joaquín Díaz-Mediavilla, Consuelo Rayón, Natalia de las Heras, Pascual Fernández-Abellán, Miguel Cabezudo, Alfonso García de Coca, Jose Mª Alonso, Carmen Olivier, Jesús Mª Hernández-Rivas, Pau Montesinos, Rosa Fernández, Julio García- Suárez, Magdalena García, María-José Sayas, Bruno Paiva, Marcos González, Alberto Orfao, Jesús F. San Miguel, Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. Leukemia Research. ,vol. 40, pp. 1- 9 ,(2013) , 10.1016/J.LEUKRES.2015.10.002

Thomas Kristensen, Michael B. Møller, Lone Friis, Olav J. Bergmann, Birgitte Preiss, NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression. European Journal of Haematology. ,vol. 87, pp. 400- 408 ,(2011) , 10.1111/J.1600-0609.2011.01673.X

W-C Chou, J-L Tang, S-J Wu, W Tsay, M Yao, S-Y Huang, K-C Huang, C-Y Chen, C-F Huang, H-F Tien, Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia. ,vol. 21, pp. 998- 1004 ,(2007) , 10.1038/SJ.LEU.2404637

James R Downing, The core-binding factor leukemias: lessons learned from murine models Current Opinion in Genetics & Development. ,vol. 13, pp. 48- 54 ,(2003) , 10.1016/S0959-437X(02)00018-7

Susanne Schnittger, Martin Weisser, Claudia Schoch, Wolfgang Hiddemann, Torsten Haferlach, Wolfgang Kern, New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood. ,vol. 102, pp. 2746- 2755 ,(2003) , 10.1182/BLOOD-2003-03-0880

Eric Jourdan, Nicolas Boissel, Sylvie Chevret, Eric Delabesse, Aline Renneville, Pascale Cornillet, Odile Blanchet, Jean-Michel Cayuela, Christian Recher, Emmanuel Raffoux, Jacques Delaunay, Arnaud Pigneux, Claude-Eric Bulabois, Céline Berthon, Cécile Pautas, Norbert Vey, Bruno Lioure, Xavier Thomas, Isabelle Luquet, Christine Terré, Philippe Guardiola, Marie C. Béné, Claude Preudhomme, Norbert Ifrah, Hervé Dombret, Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia Blood. ,vol. 121, pp. 2213- 2223 ,(2013) , 10.1182/BLOOD-2012-10-462879